A phase 1b, open-label, investigator-initiated, proof-of-concept study of pembrolizumab for advanced basal cell carcinomas

Background: A significant proportion of advanced basal cell carcinomas (BCCs) are incompletely treated with current therapies. As BCCs have particularly high mutational burdens and can express programmed death ligand (PDL)-1, we performed a proof-of-concept study of the PD-1 inhibitor, pembrolizumab, for advanced BCCs.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research